In a fast-moving regulatory flare-up around compounded weight-loss drugs, former FDA chief Scott Gottlieb said on CNBC that Hims & Hers Health, Inc. could face Department of Justice action tied to its plan to market an unapproved oral semaglutide pill—a move that also triggered legal pushback from Novo Nordisk and a sharp swing in HIMS shares. The episode spotlights tightening U.S. enforcement on compounded GLP-1s, mounting IP risk, and the cash-pay telehealth model’s exposure to drug-shortage “loopholes.”
What happened—timeline & trigger
- Feb 5: Hims announced access to compounded semaglutide pills starting at $49/month, positioning it as a budget-friendly, oral alternative to branded GLP-1s. The offer relied on pharmacy compounding, historically tolerated during shortages.
- Feb 6–7: U.S. health officials signaled stepped-up enforcement against unapproved compounded GLP-1 products, with referrals for potential DOJ action and specific concern over oral absorption and safety.
- Feb 9: Gottlieb told CNBC that Hims risks DOJ action tied to the unapproved pill, echoing the enforcement posture. Meanwhile, Novo Nordisk sued Hims after the product launch; Hims then abandoned the pill plan within days.
Why regulators care
Compounded copies aren’t FDA-approved and can only be made under narrow conditions (e.g., shortages), with strict limits on promotion. Prior FDA letters have already warned Hims about claims around compounded semaglutide, highlighting that “compounded drug products are not FDA-approved.” That history raises the risk that new oral claims could be viewed as marketing an unapproved new drug.
Legal & competitive overhang
- IP & injunction risk: Novo’s suit raises the specter of patent enforcement on oral semaglutide. Even a rapid product retreat doesn’t preclude injunctive relief and/or damages.
- Precedent risk to telehealth peers: A decisive regulatory action could chill cash-pay GLP-1 compounding across platforms and push patients back to approved brands from Novo and Eli Lilly and Company.
Market reaction & read-through
- HIMS: Shares whipsawed on enforcement headlines and the withdrawal, with heavy volumes reflecting de-risking of a high-growth telehealth name tethered to GLP-1 momentum. (See live price above.)
- NVO & LLY: Branded incumbents caught a bid on expectations of tighter policing of compounded rivals and preservation of pricing power in obesity care.
What to watch next
- Enforcement cadence: Any formal DOJ action or additional FDA letters would define the compliance perimeter for compounded GLP-1s in 2026.
- Litigation milestones: Court filings in Novo vs. Hims (scope of claims, emergency relief) and whether cases broaden to other telehealth operators.
- Supply backdrop: If branded GLP-1 shortages ease, the legal window for compounding narrows further—weakening the business case for cash-pay compounded offerings.
- Portfolio pivots: Hims’ strategy to re-emphasize approved therapies and non-GLP-1 weight-management pathways to stabilize growth.
Bottom Line for Hims & Hers
Gottlieb’s warning crystallizes a new reality: the era of permissive compounding around GLP-1s is ending. For Hims, that means higher legal and regulatory friction on any unapproved oral formulations and a likely reset toward approved-drug pathways. For investors, enforcement momentum is supportive for Novo/Lilly moats and a reminder that telehealth scale doesn’t override core FDA/DOJ guardrails.
FAQ Hims & Hers
What exactly did Gottlieb say?
That Hims could face DOJ action over marketing an unapproved GLP-1 pill—aligning with a broader FDA/HHS crackdown on compounded GLP-1s.
Did Hims & Hers keep selling the pill?
No. After the outcry and legal threats, Hims abandoned the compounded oral semaglutide plan within days of launch.
Related articles
Why are compounded GLP-1s controversial?
They lack FDA approval, rely on shortage allowances, and have raised safety/quality and promotion concerns. Prior FDA letters to Hims flagged claim-making around compounded semaglutide.
Who benefits if enforcement tightens?
Branded leaders Novo Nordisk and Eli Lilly, whose approved GLP-1 franchises face less off-label or compounded erosion.
Disclaimer
This article is for information purposes only and does not constitute investment advice or a solicitation to buy or sell any security. Markets and regulatory outcomes can change rapidly. Always conduct your own research and consider consulting a licensed financial professional.
